Clinical Trial Update: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating flotetuzumab for relapsed or refractory CD123-positive hematologic malignancies has completed, providing initial safety and activity …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Lymphoblastic Leukemia T-cell
• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Chronic Myeloid Leukemia Bcr-abl1 Positive
• Hairy Cell Leukemia
• Hodgkin Lymphoma
• Systemic Mastocytosis

Drugs mentioned

• Flotetuzumab (flotetuzumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED